Scholar Rock price target raised to $37 from $27 at Wedbush

Wedbush raised the firm’s price target on Scholar Rock to $37 from $27 and keeps an Outperform rating on the shares following the release of figures accompanying top-line SAPPHIRE data. Key highlights include longitudinal comparisons suggesting likely regulatory approval, upward revision of the firm’s sales estimates, and read-through to obesity, Wedbush says. For investors looking for validation of Scholar Rock’s myostatin-selective platform, the firm emphasizes multiple opportunities remain for shares to appreciate over the coming year as clarity emerges over subgroup performance and fine-tuning of a likely label.